Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-000788

← back to feed
Filed
Apr 22, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Apr 17, 2026 207.03M sh
Current Liabilities Q2 2025 · Jul 31, 2024 $3.77M
Current Liabilities Q2 2025 · Jan 31, 2024 $3.49M
Total Liabilities Q2 2025 · Jul 31, 2024 $3.77M
Total Liabilities Q2 2025 · Jan 31, 2024 $3.49M
Current Assets Q2 2025 · Jul 31, 2024 $45.25K
Current Assets Q2 2025 · Jan 31, 2024 $23.63K
Total Assets Q2 2025 · Jul 31, 2024 $64.33K
Total Assets Q2 2025 · Jan 31, 2024 $137.34K
Shares Diluted Q2 2025 · Jul 31, 2023 207.03M sh
Shares Diluted Q2 2025 · Jul 31, 2023 207.03M sh
Operating Cash Flow Q2 2025 · Jul 31, 2023 −$27.75K
Stockholders Equity Q2 2025 · Jul 31, 2023 −$2.97M
Stockholders Equity Q2 2025 · Apr 30, 2023 −$2.66M
Stockholders Equity Q2 2025 · Jan 31, 2023 −$2.4M
Eps Diluted Q2 2025 · Jul 31, 2023 $0.00
Eps Diluted Q2 2025 · Jul 31, 2023 $0.00
Sga Expense Q2 2025 · Jul 31, 2023 $353.58K
Sga Expense Q2 2025 · Jul 31, 2023 $658.18K
Net Income Q2 2025 · Jul 31, 2023 −$353.58K
Net Income Q2 2025 · Jul 31, 2023 −$658.18K
Net Income Q2 2025 · Apr 30, 2023 −$304.6K
Operating Income Q2 2025 · Jul 31, 2023 −$353.58K
Operating Income Q2 2025 · Jul 31, 2023 −$658.18K
Revenue Q2 2025 · Jul 31, 2023 $0
Revenue Q2 2025 · Jul 31, 2023 $0